Results 71 to 80 of about 26,940 (220)

Integrated Clinical and Proteomic Profiling of CD19 Chimeric Antigen Receptor T Cell Therapy in Progressive Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia, Wanyi Lin, Zhangyi Zhao, Fenglin Wu, Chaoyu Gu, Yuankai Sun, Zhe Ding, Chang Wei, Xinyu Li, Cuiwei Xie, Peng Xia, Zhen Xia, Xuesong Liu, Shaoying Yang, Chunyan Zhang, Hanlin Yin, Liangjing Lu   +16 more
wiley   +1 more source

Expert Perspectives: Defining and Managing Progressive Pulmonary Fibrosis in Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Systemic sclerosis–associated interstitial lung disease (SSc‐ILD) is one of the leading causes of morbidity and mortality in SSc, affecting up to three‐quarters of patients. The disease course is highly heterogeneous, ranging from indolent, nonprogressive forms to rapidly progressive pulmonary fibrosis (PPF).
Devis Benfaremo, Dinesh Khanna, Corrado Campochiaro, Vincent Cottin, Fabrizio Luppi, Marco Matucci‐Cerinic, Gianluca Moroncini, Yannick Allanore   +7 more
wiley   +1 more source

Comparative Transcriptional Profiling of Key Macrophage and Fibroblast Subpopulations in Rheumatoid Arthritis–Associated Lung Disease

Arthritis &Rheumatology, EarlyView.
Objective Rheumatoid arthritis (RA) often involves extra‐articular complications, including interstitial lung disease (ILD) and/or pulmonary nodules. Transcriptomic profiling of lung tissue provides the opportunity to directly assess cell‐specific gene expression and corresponding pathway activation in different types of rheumatoid lung disease ...
Tracy Tabib, Ogechukwu Ezenwa, Joshua Sciurba, Eleanor B. Valenzi, John Sembrat, Brittany Cody, Jishnu Das, Robert Lafyatis, Dana P. Ascherman   +8 more
wiley   +1 more source

Band-like Acral Osteolysis in Limited Cutaneous Scleroderma

International Journal of Clinical & Medical Imaging, 2016
Abstract: Acral osteolysis is a well-recognized manifestation of scleroderma. Scleroderma is characterized by abnormal deposition of collagen and other extra cellular matrix macromolecules leading to vascular damage, inflammation and tissue fibrosis.
Synrang B Warjri, Baphiralyne Wankhar, Animesh Mishra   +2 more
openaire   +1 more source

Outcomes in progressive pulmonary fibrosis in systemic autoimmune rheumatic diseases: real‐world data from the ILD‐PRO Registry

Arthritis &Rheumatology, Accepted Article.
Objective We evaluated baseline characteristics, treatment patterns, and outcomes in patients with systemic autoimmune rheumatic disease‐associated progressive pulmonary fibrosis (SARD‐PPF) and evaluated whether outcomes differed by SARD subtype. Methods The ILD‐PRO Registry is a prospective multicenter US registry of patients with PPF.
Sonali J Bracken, Jeremy M Weber, Megan L Neely, Aparna C Swaminathan, Scott M Palmer, Erin M Wilfong, Ann D Chauffe, Elizabeth R Volkmann   +7 more
wiley   +1 more source

High-content Image-based Drug Testing of Patients’ Primary Fibroblasts Reveals Potential New Treatment Options for Localized Scleroderma

Acta Dermato-Venereologica
Localized scleroderma is a rare autoimmune disease characterized by progressive fibrosis of the skin and its underlying structures, causing loss of normal tissue structure and function.
Katariina Mähönen, Isabel Mogollon, Antti Hassinen, Minttu Polso, Katja Välimäki, Swapnil Potdar, Al-Amin Chowdhury, Annamari Ranki, Jani Saarela, Vilja Pietiäinen, Jaana Panelius   +10 more
doaj   +1 more source

GLP‐1 Receptor Agonists and Endoscopy: Understanding Gastric Stasis, Aspiration Risk, and Contemporary Peri‐Procedural Guidance

Chronic Diseases and Translational Medicine, EarlyView.
Pharmacological mechanisms and physiologic effects of GLP‐1 receptor agonists relevant to peri‐endoscopic risk. ABSTRACT The global increase in obesity, type 2 diabetes mellitus (T2DM), and metabolic dysfunction‐associated steatotic liver disease (MASLD) has led to a higher use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) among patients ...
Junaid Beig, Jason Ta, Sophie Jones, Emily Scott, Khalid Sofi, Frances Osler, Marije Jansen, Puneet Chhabra   +7 more
wiley   +1 more source

Outcomes of lung transplantation for scleroderma versus other indications: Insigts from a single center

JHLT Open
Background: Scleroderma is an autoimmune disease affecting the skin and internal organs, with pulmonary disease being the leading cause of mortality.
Masashi Furukawa, MD PhD, Ernest G. Chan, MD MPH, John P. Ryan, PhD, Chadi A. Hage, MD, Pablo G. Sanchez, MD PhD   +4 more
doaj   +1 more source

Parenteral nutrition and hospital outcomes in Australian adults: A descriptive cohort study

Journal of Parenteral and Enteral Nutrition, EarlyView.
Abstract Background There is limited information regarding real‐world use of parenteral nutrition in hospitals. The objective of the study was to provide a real‐world description of parenteral nutrition administration in hospitalized patients. Methods This was a descriptive cohort study in 507 hospitalized adults who received parenteral nutrition at ...
Frank M. P. van Haren, Sumeet Rai, Andrew Thomson, Josie Russell‐Brown, Mary Nourse, Shakira Spiller, Louise Herlihy, Sean Weng Chan, Peter Velloza, Matthew H. Anstey, Robert N. Palmer, Bianca Mammana, Tania Elderkin, Adam Visser, Matt Brain, Sarah Mineall, Emma J. Ridley   +16 more
wiley   +1 more source

Assessment of Treatment Response in Patients With Scleromyxedema by the Double Modified Rodnan Skin Score

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Scleromyxedema (SMX) is a cutaneous mucinosis characterised by an abnormal accumulation of mucin in the skin and limited treatment options. Assessment of therapy response during treatment is challenging. Objectives Patients with SMX receiving high‐dose intravenous IVIg therapy were included to assess validity of the double modified ...
Julia K. Winkler, Alexander H. Enk
wiley   +1 more source